Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Free Cash Flow (2018 - 2025)

UroGen Pharma (URGN) has disclosed Free Cash Flow for 8 consecutive years, with -$38.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 179.18% year-over-year to -$38.3 million, compared with a TTM value of -$162.7 million through Dec 2025, down 67.66%, and an annual FY2025 reading of -$162.7 million, down 67.66% over the prior year.
  • Free Cash Flow was -$38.3 million for Q4 2025 at UroGen Pharma, up from -$42.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$13.1 million in Q4 2023 and bottomed at -$42.4 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$25.5 million, with a median of -$23.9 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 40.03% in 2023, then crashed 179.18% in 2025.
  • Year by year, Free Cash Flow stood at -$20.3 million in 2021, then dropped by 7.36% to -$21.8 million in 2022, then soared by 40.03% to -$13.1 million in 2023, then dropped by 5.23% to -$13.7 million in 2024, then plummeted by 179.18% to -$38.3 million in 2025.
  • Business Quant data shows Free Cash Flow for URGN at -$38.3 million in Q4 2025, -$42.4 million in Q3 2025, and -$40.0 million in Q2 2025.